Zydus will enter a competitive field, with an FDA decision on CymaBay s PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease."
Saroglitazar Mg, approved by the DCGI, is an innovative drug from Zydus to treat chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato Hepatitis (NASH).
Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India s DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.
(Bloomberg) After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.
Even as boosters are likely to keep demand alive for COVID-19 inoculations worldwide, the desperate shortages that existed for much of last year have waned.